

# Status Listing of New Drugs Introduced

In September 2001, the PMPRB began providing information on the status of the price review for each drug product. The Board had agreed with one of the recommendations of the Working Group on Price Review Issues to make information on the status of the price review of individual drug products publicly available.

**Starting with the new patented medicines introduced in 2005**, the status column will report information as follows: Under Review, Under Investigation, Within Guidelines, VCU (Voluntary Compliance Undertaking), NOH (Notice of Hearing).

A new patented medicine is under review when it first comes under the jurisdiction of the PMPRB, that is when it is patented and

sold. When the review is complete, the price of the drug product is either within the Guidelines or under investigation. A drug product will come under investigation when it appears that the criteria for commencing an investigation have been triggered.

An investigation provides a further opportunity to the patentee to provide additional information. There are three possible results of this further review: the price is found to be within the Guidelines, the patentee submits a Voluntary Compliance Undertaking, the Chairperson issues a Notice of Hearing.

For more information on this matter, patentees may want to contact the Compliance Officer assigned to their company. ■

See Schedule 5 of the *Compendium of Guidelines, Policies and Procedures* for further information on the criteria for commencing an investigation.

**The list of new patented drugs which come under the jurisdiction of the PMPRB in a given year is available on our Web site under Patented Medicines.**

*Published in the April 2005 NEWSletter*